Triple-negative breast cancer (TNBC), defined as tumors with no expression of the estrogen receptor (ER) nor progesterone receptor (PR), and with no amplification of the human epidermal growth factor-2 (HER2) gene, accounts for about 15–20% of the more than one million breast cancers diagnosed worldwide annually [1,2]. Here, ESR1 is linked to breast carcinoma.